P-ISSN: 2808-0467
E-ISSN: 2808-5051
Homepage: https://iss.internationaljournallabs.com/index.php/iss
1270 This work is licensed under CC BY-SA 4.0
CAPITAL STRUCTURE ANALYSIS IN HEALTHCARE ISSUERS IN
THE DES CATEGORY FOR 2017-2019
Taufik Riyandi
1
, Setyo Riyanto
2
Master of Management, Mercu Buana Univeristy, Central Jakarta, DKI Jakarta, Indonesia
1
taufik.riyandi@outlook.com
2
setyo.riyanto@mercubuana.ac.id
PAPER INFO ABSTRACT
Received: July
2022
Revised: July
2022
Approved: July
2022
Background: There is an increasing trend of sustainable healthy lifestyles
and strong industrial potential amid a pandemic. To seize this opportunity,
health companies need to increase their production capacity, and ultimately
the company needs capital for its operations. Thus, it is necessary to analyze
the optimal capital structure to reduce so that the company can maximize its
value of the company.
Aim: This study aims to analyze the company's cost of capital and analyze
the optimal capital structure of the company in the pharmaceutical industry
on the Sharia Stock List (DES), which is listed on the Indonesia Stock
Exchange (IDX) for 2017-2019 period.
Method: The analysis was carried out by calculating the WACC, then
comparing the average industrial WACC with the average value of the
pharmaceutical industry companies so that they could analyze the capital
structure optimally for each issuer. Calculation using Microsoft Excel 2016.
Findings: The average industrial issuer was dominated by the capital
structure originating from equity. In addition, the calculation of the industrial
average WACC and the average value of industrial companies is 8.00% and
Rp. 374,302,- (in Millions of Rupiah) where KLBF is a pharmaceutical issuer
that has an optimal capital structure, namely WACC below the industry
average and company value above the industry average. There is company
management that is more careful and careful in determining the company's
capital structure, even for working capital and or for investment, so that an
optimal combination is achieved and can increase company value and reduce
company risk.
KEYWORDS
capital structure, firm value, cost of capital, optimal capital structure
INTRODUCTION
One of the government programs focuses on improving the quality of the nation's health,
there is a demand gap between the direction of business and household (Consumption)
tendencies.
Figure 1. Business Tendency Index (ITB) and Consumption Tendency Index (ITK) 2019
Source: bps.go.id, processed data
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1271 Interdisciplinary Social Studies, 1(10), Jul 2022
Predictions of the economic outlook can be made using various analytical instruments,
including the Business Tendency Index (Indeks Tendensi Bisnis, ITB) and the Consumer
Tendency Index (Indeks Tendensi Konsumen, ITK). ITB provides an overview of economic
conditions in the current quarter and one quarter ahead according to the perception of
entrepreneurs (Diarga, 2020). Meanwhile, ITK provides an overview of economic conditions
in the current quarter and the next quarter according to consumer (Household) perceptions
(Diarga, 2020).
It is not quite there yet. In the presentation of ITB and ITK, the trend shows a decline
caused by global economic uncertainty which results in fluctuations in the Rupiah against the
dollar which has an impact on consumer companies that rely on exports and imports, both
supply and distribution of their products. However, this difficulty is not an obstacle because
the potential for the high demand for household consumption in ITK always leads to a trend
above the estimated direction of the ITB business, the great potential at this level of demand
makes a business opportunity to fulfill it. In addition, there is an increase in the trend of healthy
lifestyle sustainable, guarantees for health, increasing population growth, and strong industrial
potential amid a pandemic will have an impact on the increasing need for health services.
To seize this opportunity, healthcare companies need to increase production capacity and
in the end, the company needs capital for its operations with the support of appropriate
localization management so it is necessary to analyze the optimal capital structure to reduce
risks so that the company can maximize company value (Amdalena, 2021). According to
Achmad (2018), "The capital structure that can maximize the share price is a structure that can
minimize WACC". "The optimal capital structure is the mix of debt, preferred stock, and
common equity that maximizes the stock's intrinsic value. As we will see, the capital structure
that maximizes the intrinsic value also minimizes the WACC" (Brigham & Houston, 2019).
Therefore, the smaller the weighted average cost of capital, the more it will be able to maximize
the value of the company.
Corporate value is used as a measuring tool for the company's success in achieving
company management goals (Suranto & Walandouw, 2017). Assessing companies, one of
which can be obtained using the stock valuation method which uses the concept of the time
value of money using Free Cash Flow (FCF) and discounting using the weighted average cost
of capital (WACC) to get optimal value in carrying out investments (Islami, 2020). The
objectives of the company's management can be achieved if the company's decision in
establishing its capital structure is optimal (Pantow et al., 2015). The establishment of an
optimal capital structure will bring good corporate value.
Studies that discuss the analysis of the optimal capital structure using WACC calculations
and company value have been carried out. Rahma et al. (2014) researched the analysis of
determining the optimal capital structure to increase the value of the company (study on PT.
Seemount Garden Sejahtera, Jiwan, Madiun Regency for the period 2011-2013). Netriyana
(2014) analyzes the optimum capital structure of telecommunications companies listed on the
IDX for the period 2008-2012. Septantya et al. (2015) namely determine the optimal capital
structure to increase the value of the company's shares in PT. Pt. Perusahaan Gas Negara
(Persero) Tbk. period 2011-2013. The next research conducted by Sulistio & Saifi (2017) is
the analysis of determining the optimal capital structure to increase the value of the study
company at PT. Astra Graphia Tbk for the 2013-2015 period and other research was also
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1272 Interdisciplinary Social Studies, 1(10), Jul 2022
conducted by Yuliana & Wijayanti (2017) who analyzed the optimum capital structure of
cement industry companies listed on the IDX for the 2013-2015 period.
Based on the five studies, there is any inconsistency between the results of the previous
study which shows that capital structure, especially the cost of capital, does not always play an
important role in the size of the company's value. This condition encourages researchers to find
out more about the capital structure of companies in other sectors, such as healthcare issuers in
the pharmaceutical sub-sector of the DES category for the 2017-2019 period. In addition, the
calculation of capital costs and the analysis of the optimal capital structure in companies that
go public in Indonesia is also still rarely carried out. So that this study aims to analyze the
proportion of capital structure composition, capital costs, and company value and analyze the
optimal capital structure in the pharmaceutical sub-sector industry healthcare in the DES
category listed on the IDX for the 2017-2019 period.
METHOD
The type of this research is descriptive research with a quantitative approach, where the
researcher will describe the determination of the optimal capital structure to increase company
value through the analysis of financial statements as a tool for the validity of the information.
There were a total of 11 companies in the pharmaceutical sub-sector that were the
population in this study. The sample from this study based on the purposive sampling method
to 8 companies, namely PT. Darya-Varia Laboratoria Tbk. (DVLA), PT. Indofarma Tbk.
(INAF), PT. Kimia Farma Tbk. (KAEF), PT. Kalbe Farma Tbk. (KLBF), PT. Merck Indonesia
Tbk. (MERK), PT. Pyridam Farma Tbk. (PYFA), PT. Industri Jamu dan Farmasi Sido Tbk.
(SIDO), and PT. Tempo Scan Pacific Tbk (TSPC).
The data analysis method in this study was carried out by calculating the WACC, then
comparing it with the industry average WACC value and combining it with the company's
value so that it can be analyzed for the optimal capital structure of the pharmaceutical subsector
issuers listed on the DES of the Indonesia Stock Exchange for the 2017-2019 period. The
calculation is done using Microsoft Excel 2016 software. The steps for data analysis in this
study are as follows:
1) Collecting data, namely financial statements and annual reports of pharmaceutical sub-
sector issuers listed on the DES of the Indonesia Stock Exchange for the 2017-2019
research period;
2) Calculating the relative valuation of the issuer's financial structure including DR, DER,
and LDER;
3) Calculates the cost of capital (COC) on the composition of the capital structure of the
enterprise. For the cost of debt, the cost of equity then calculates the weighted average
cost of capital (WACC);
4) The industry WACC value is averaged, then calculates as the company value; and
5) Analyze the optimization of the company's capital structure by comparing the WACC
value between companies with the industry average WACC value, then combining it
with the company value.
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1273 Interdisciplinary Social Studies, 1(10), Jul 2022
RESULTS AND DISCUSSION
Cost of Capital
Capital costs are costs that have been incurred because the company uses sources of funds
incorporated in the capital structure (Atiqoh & Asyik, 2016). The capital structure relates to
the company's permanent spending structure consisting of long-term debt, ordinary shares, and
preferred shares (Elvina et al., 2021). In this study, the calculation of preferred shares was not
carried out because pharmaceutical issuers in the DES category listed on the IDX did not issue
preferred shares.
Debt Costs
The results of the calculation of the cost of long-term debt of pharmaceutical issuers are
as follows:
Table 1. Pharmaceutical Industry Debt Costs for the 2017-2019 Period
Debt Cost (𝑹
𝒅
)
Company
Year
𝑹
𝒅
𝑹
𝒅
(1-T)
DVLA
2017
0,00%
0,00%
2018
0,00%
0,00%
2019
0,00%
0,00%
INAF
2017
1,70%
1,28%
2018
2,42%
1,81%
2019
8,99%
6,74%
KAEF
2017
5,67%
4,25%
2018
4,50%
3,37%
2019
5,07%
3,80%
KLBF
2017
3,97%
3,17%
2018
8,74%
6,99%
2019
16,02%
12,82%
MERK
2017
0,00%
0,00%
2018
0,00%
0,00%
2019
0,00%
0,00%
PYFA
2017
0,21%
0,16%
2018
2,08%
1,56%
2019
2,18%
1,64%
SIDO
2017
0,00%
0,00%
2018
0,00%
0,00%
2019
0,00%
0,00%
TSPC
2017
0,93%
0,70%
2018
1,78%
1,34%
2019
4,73%
3,54%
Source: Financial Statements, Data Processed
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1274 Interdisciplinary Social Studies, 1(10), Jul 2022
The result of the calculation of the cost of debt after tax (RdT) is not found on the DVLA.
therefore, the implementation of the DVLA liquidity risk management policy from 2017-2019
is to maintain adequate liquid financial assets. DVLA's liquid financial assets (cash and cash
equivalents) exceed financial liabilities and DVLA does not have any loans subject to interest.
Therefore, DVLA does not have substantial exposure to liquidity risks that may arise from
imbalances over the maturity of assets and financial liabilities in the future. So that there are
no debt costs to this company.
The results of the calculation of INAF's cost of debt after tax (RdT) for the 2017-2019
period are increasing every year. RdT in 2017 was 1.28%, increased in 2018 by 1.81%, and in
2019 increased by 6.74%. This is due to the cost of debt before tax (Rd) in 2017, 2018, and
2019 of 1.70%, 2.42%, and 8.99%, respectively. The Rd increase event in 2018 was due to an
increase in the company's operating debt caused by an increase in bank loans for the
establishment of a Large Volume Parenteral (LVP) factory in Eastern Indonesia as a follow-up
to the signing of the Joint Venture Business cooperation. Meanwhile, the increase in Rd in
2019 was due to the company getting approval for restructuring short-term to long-term loans
from PT Bank Mandiri (Persero) Tbk and PT Bank Negara Indonesia (Persero) Tbk for the
credit facilities provided by the two banks to the company. As a result of the change in loan
restructuring, it has led to a significant increase in long-term liabilities.
The results of the calculation of KAEF's cost of debt after tax (RdT) for the 2017-2019
period are relatively decreasing every year. RdT in 2017 was 4.25%, decreased in 2018 by
3.38%, and in 2019 increased by 3.80%. This is due to the cost of debt before tax (Rd) in 2017,
2018, and 2019 of 5.67%, 4.50%, and 5.07%, respectively. The Rd decrease event in 2018 was
caused by the repayment of Medium Term Notes of Rp 200,000 million and an increase in
2019 there was the issuance of Medium Term Notes of Rp 500,000 million. In addition, there
was an increase in long-term bank debt caused by the company's increasing investment to
finance the Banjaran Factory project in Bandung, the acquisition of PT Phapros Tbk, and other
investments.
The results of the calculation of the cost of debt after tax (RdT) KLBF for the period 2017-
2019 are increasing every year. RdT in 2017 was 3.17%, increased in 2018 by 6.99%, and in
2019 increased by 12.82%. This is due to the cost of debt before tax (Rd) in 2017, 2018, and
2019 of 3.97%, 8.74%, and 16.02%, respectively. The Rd increase event in 2018 was due to
the company having long-term bank debt, namely investment loans denominated in Rupiah to
PT Bank Central Asia Tbk, MUFG Bank, and Citibank. To be given to a subsidiary, namely
PT. Saka, PT. Toedjoe Star, and PT. WE. The increase in Rd in 2019 was due to the same
activities carried out in 2018. The increase in the cost of debt (Rd) in 2017-2019 affected the
value of the cost of debt after tax or (RdT). The Rd value here is derived from the borrowing
costs contained in the company's financial statements consisting of interest costs and
amortization of transaction costs on long-term bank loans. The amount of income tax rate from
KLBF in 2017-2019 was 20% because the company had met the tax incentive requirements,
namely obtaining a reduction in the Corporate PPH rate by 5% each for the 2017-2019 fiscal
year based on PP No. 81 of 2007. These requirements include, namely, a decrease in the Income
Tax Rate given to Domestic Corporate Taxpayers in the form of a Public Company if the
amount of public share ownership is 40% (forty percent) or more than the total paid-up shares
and the shares are owned by at least 300 parties. Each Party may only own less than 5% of the
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1275 Interdisciplinary Social Studies, 1(10), Jul 2022
total paid-up shares. These provisions must be fulfilled by Domestic Corporate Taxpayers in
the form of a Public Company within a minimum of 6 (six) months within 1 tax year.
The result of the calculation of the cost of debt after tax (RdT) is not found on the MERK.
Due to the implementation of the company's policy in managing MERK liquidity risk from
2017-2019, it is to maintain adequate liquid financial assets by conducting continuous
monitoring of projected and actual cash flows. Therefore, the company meets the needs of
funds for the next period.
The results of PYFA's cost of payables after tax (RdT) calculation in 2018 increased from
2017 and increased in 2019. RdT in 2017 was 0.16%, increased in 2018 by 1.56%, and in 2019
increased by 1.64%. This is due to the cost of debt before tax (Rd) in 2017, 2018, and 2019 of
0.21%, 2.08%, and 2.18%, respectively. The event of increasing Rd in 2018 was due to long-
term bank debt for land acquisition of the Company's office, namely for the construction of the
Company's new office in Pagedangan, Tangerang Regency. The increase in Rd in 2019 was
due to the company's financial operations supported by Bank OCBC NISP which provided a
Demand Loan of Rp. 27,610,000,000,-. The company also received a Current Account loan
from Bank BCA in the amount of Rp. 4,900,000,000,-. Meanwhile, Bank OCBC NISP also
provided a loan of Rp. 8,415,000,000 in the form of a Term Loan which was used by the
company to buy a plot of land covering an area of 3,400 m
2
in Jakarta.
The result of the calculation of the cost of debt after tax (RdT) is not found in SIDO. Due
to the implementation of liquidity risk management policies from 2017-2019 where SIDO
mitigates liquidity risks by analyzing the availability of cash flows and funding structures so
that the performance produced can meet the funding of the company's operating activities for
the next period. The company monitors its every liquidity need by monitoring the schedule of
payment of financial liabilities and cash outflows related to day-to-day operations, to ensure
the availability of sufficient funding, both binding and non-binding. In addition, the
implementation of the policy on credit risk faced by SIDO comes from the placement of current
accounts and deposits in banks and credit provided to customers. Apart from the above
disclosures, SIDO does not have a concentration of credit risk therefore for the period ended
December 31, 2017, 2018, and 2019. SIDO's financial fee account is a bank-only administrative
fee with a value of Rp588,000,000,-, Rp141,000,000 and Rp154,000,000,000,- respectively.
The results of the calculation of the cost of debt after tax (RdT) of PT Tempo Scan Pacific
Tbk in 2018 experienced an increase from 2017 and an increase in 2019. RdT in 2017 was
0.70%, increased in 2018 by 1.34%, and in 2019 decreased by 3.54%. This is due to the cost
of debt before tax (Rd) in 2017, 2018, and 2019 of 0.93%, 1.78%, and 4.73%, respectively.
The calculation of Rd is contained in appendix 13. The event of an increase in Rd in 2018 was
due to an increase in the company's debt, namely debt to PT Bank HSBC Indonesia for working
capital and an increase in overdraft. Meanwhile, the increase in Rd in 2019 was due to an
increase in the amount of long-term bank debt for working capital at PT Bank HSBC Indonesia.
Equity Fees
In this study, the calculation of the cost of equity capital was carried out using the Capital
Asset Pricing Model (CAPM) approach. In the CAPM formulation, there are various variables
including the Risk-free rate (𝑅
𝑓
) obtained from the Bank Indonesia Syariah Certificate
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1276 Interdisciplinary Social Studies, 1(10), Jul 2022
(Sertifikat Bank Indonesia Syariah, SBIS) for 12 months. Stock beta (𝛽)which is a systematic
risk of the market (Uncontrollable turmoil) is calculated manually using the variable rate price
{Covarians (Rate of individual Issuers; Index rate) divided by variance (Index Rate)} between
each issuer and index, the index under reference is JII. The meaning of beta (𝛽) itself is that if
the beta is positive, then the movement of stock prices is in the same direction as the movement
of the market index. Based on the size of the stock beta number, it can be divided into Beta <
1, in the long run, the volatility of the stock's return will be in the same direction as the market
index, but with less volatility; Beta = 1, in the long run, the volatility of the stock's return will
be in the same direction as the market index, with volatility equal to the volatility of the market;
Beta > 1, in the long run, the volatility of stock returns will be in the same direction as the
market index, with greater volatility. The return market rate 𝑅
𝑚
uses a monthly price return
from JII. From the results of the calculation of the cost of equity (𝑅
𝑒
) of the eight
pharmaceutical issuers are presented in the following table:
Table 2. Pharmaceutical Industry’s Cost of Equity for the Period of 2017-2019
Cost of Equity (𝑹
𝒆
)
Company
Year
𝑹
𝒇
β (JII)
𝑹
𝒎
(JII)
𝑹
𝒆
(JII)
DVLA
2017
5,75%
0,0480
8,64%
7,89%
2018
6,03%
-0,1582
6,17%
8,01%
2019
6,16%
0,5302
-11,31%
1,90%
INAF
2017
5,75%
0,2038
8,64%
8,34%
2018
6,03%
3,2999
6,17%
8,48%
2019
6,16%
-4,3661
-11,31%
84,47%
KAEF
2017
5,75%
0,1322
8,64%
8,13%
2018
6,03%
0,6054
6,17%
8,11%
2019
6,16%
0,5667
-11,31%
3,86%
KLBF
2017
5,75%
-0,0166
8,64%
7,70%
2018
6,03%
0,2925
6,17%
8,07%
2019
6,16%
0,4293
-11,31%
3,66%
MERK
2017
5,75%
-0,0050
8,64%
7,73%
2018
6,03%
-0,2149
6,17%
8,00%
2019
6,16%
0,6796
-11,31%
1,29%
PYFA
2017
5,75%
-0,0070
8,64%
7,73%
2018
6,03%
0,1189
6,17%
8,05%
2019
6,16%
-0,3873
-11,31%
14,93%
SIDO
2017
5,75%
-0,0054
8,64%
7,73%
2018
6,03%
-0,3623
6,17%
7,98%
2019
6,16%
-0,4862
-11,31%
16,66%
TSPC
2017
5,75%
0,0038
8,64%
7,76%
2018
6,03%
-0,0820
6,17%
8,02%
2019
6,16%
-0,6224
-11,31%
19,04%
Source: Financial Statements, Data Processed
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1277 Interdisciplinary Social Studies, 1(10), Jul 2022
The results of the calculation of the cost of equity (Re) DVLA for the 2017-2019 period
have decreased relatively. In 2017 it was 7.89% an increase in 2018 by 8.01% and decreased
in 2019 by 1.90%.
The results of the calculation of INAF's cost of equity (Re) for the 2017-2019 period
increased. In 2017 it was 8.34% an increase in 2018 by 8.48% and an increase in 2019 by
84.47%.
The results of the calculation of KAEF's cost of equity (Re) for the 2017-2019 period have
decreased relatively. In 2017 it was 8.13% an increase in 2018 by 8.11% and an increase in
2019 by 3.86%.
The results of the calculation of the cost of equity (Re) KLBF for the period 2017-2019 are
relatively declining. In 2017 it was 7.70% an increase in 2018 by 8.07% and a decrease in 2019
by 3.86%.
The results of the calculation of the cost of equity (Re) of MERK for the 2017-2019 period
have decreased relatively. In 2017 it was 7.73% an increase in 2018 by 8.00% and a decrease
in 2019 by 1.29%.
The results of the calculation of PYFA's cost of equity (Re) for the period 2017-2019 are
relatively increased. In 2017 it was 7.73% an increase in 2018 by 8.05% and an increase in
2019 by 14.93%.
The results of the calculation of SIDO's cost of equity (Re) for the 2017-2019 period have
increased relatively. In 2017 it was 7.73% an increase in 2018 by 7.98% and an increase in
2019 by 16.66%.
The results of the calculation of TSPC's cost of equity (Re) for the period 2017-2019
increased. In 2017 it was 7.76% an increase in 2018 by 8.02% and an increase in 2019 by
19.04%.
Weighted Average Cost of Capital (WACC)
In this WACC calculation, there are no fees on preferred shares in pharmaceutical issuers.
The calculation can be seen in the following table:
Table 3. WACC Pharmaceutical Period of 2017-2019
Company
WACC (%)
2017
2018
2019
DVLA
7,89%
8,01%
1,90%
INAF
3,71%
4,11%
35,10%
KAEF
5,89%
5,05%
3,83%
KLBF
6,96%
7,90%
5,27%
MERK
7,73%
8,00%
1,29%
PYFA
5,32%
5,68%
10,33%
SIDO
7,73%
7,98%
16,66%
TSPC
5,53%
5,95%
14,26%
Source: Financial Statements, Data Processed
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1278 Interdisciplinary Social Studies, 1(10), Jul 2022
The calculation results of the WACC DVLA for the 2017-2019 period have decreased
relatively. In 2017 it was 7.89% an increase in 2018 by 8.01% and decreased in 2019 by -
1.90%. Such fluctuations in the value of WACC are due to the composition and costs of its
capital structure. In 2017-2019 the company did not have debt costs caused by the company's
policy of not having any loans that were charged interest so the company did not have a large
exposure to interest rate risk. That way from 2017-2019, the company's capital structure does
not have a combination of capital costs but is only financed by 100% equity. In 2017 the cost
of equity was 7.89%. In 2018 the cost of equity was 8.01%. In 2019 the cost of equity was
1.19%.
The calculation results of the WACC INAF for the 2017-2019 period have relatively
increased. In 2017 it was 3.29% an increase in 2018 by 3.11% and an increase in 2019 by
35.10%. Such fluctuations in the value of WACC are due to the composition and costs of its
capital structure. In 2017 the proportion of debt was higher than the proportion of equity at
65.59% and 34.41%. As for debt costs of 1.28% and equity costs of 8.34%. In 2018, the
proportion of debt was higher than the proportion of equity at 65.57% and 34.43%. As for debt
costs at 1.81% and equity costs at 8.48%. In 2019, the proportion of debt was higher than the
proportion of equity, namely 63.51% and 36.49%. As for debt costs of 6.74% and equity costs
of 84.47%.
The calculation results of the WACC KAEF for the 2017-2019 period have decreased
relatively. In 2017 it was 5.89% decreased in 2018 by 5.05% and decreased in 2019 by 3.83%.
Such fluctuations in the value of WACC are due to the composition and costs of its capital
structure. In 2017 the proportion of debt was higher than the proportion of equity at 57.80%
and 42.20%. As for debt costs at 4.25% and equity costs at 8.13%. In 2018, the proportion of
debt was higher than the proportion of equity at 64.52% and 35.48%. As for debt costs at 3.37%
and equity costs at 8.11%. In 2019, the proportion of debt was higher than the proportion of
equity at 59.61% and 40.39%. As for debt costs of 3.80% and equity costs of 3.86%.
The calculation results of the WACC KLBF for the 2017-2019 period have decreased
relatively. In 2017 it was 6.96% an increase in 2018 by 7.90% and a decrease in 2019 by 5.27%.
Such fluctuations in the value of WACC are due to the composition and costs of its capital
structure. In 2017 the proportion of debt was lower than the proportion of equity at 16.38% and
83.62%. As for debt costs of 3.17% and equity costs of 7.70%. In 2018, the proportion of debt
was lower than the proportion of equity, namely 15.71% and 84.29%. As for the cost of debt
at 6.99% and the cost of equity at 8.07%. In 2019, the proportion of debt was lower than the
proportion of equity, namely 17.56% and 82.44%. As for debt costs of 12.82% and equity costs
of 3.66%.
The calculation results of the WACC MERK for the 2017-2019 period have decreased
relatively. In 2017 it was 7.73% an increase in 2018 by 8.00% and a decrease in 2019 by 1.29%.
Such fluctuations in the value of WACC are due to the composition and costs of its capital
structure. In 2017-2019 the company did not have debt costs caused by the company's policy,
namely the company's policy in managing liquidity risk from 2017-2019 is to maintain
adequate liquid financial assets by conducting continuous monitoring of projected and actual
cash flows. That way from 2017-2019, the company's capital structure does not have a
combination of capital costs but is only financed by 100% equity. In 2017 the cost of equity
was 7.73%. In 2018 the cost of equity was 8.00%. In 2019 the cost of equity was 1.29%.
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1279 Interdisciplinary Social Studies, 1(10), Jul 2022
The calculation results of the WACC PYFA for the 2017-2019 period have relatively
increased. In 2017 it was 5.32% an increase in 2018 by 5.68% and an increase in 2019 by
10.33%. Such fluctuations in the value of WACC are due to the composition and costs of its
capital structure. In 2017 the proportion of debt was lower than the proportion of equity at
31.78% and 68.22%. As for debt costs of 0.16% and equity costs of 7.73%. In 2018 the
proportion of debt was lower than the proportion of equity, namely 36.42% and 63.58%. As
for the cost of debt of 1.56% and the cost of equity of 8.05%. In 2019, the proportion of debt
was lower than the proportion of equity at 34.63% and 65.37%. As for debt costs at 1.64% and
equity costs at 14.93%.
The calculation results of the WACC SIDO for the 2017-2019 period have relatively
increased. In 2017 it was 7.73% decreased in 2018 by 7.98% and increased in 2019 by 16.66%.
Such fluctuations in the value of WACC are due to the composition and costs of its capital
structure. In 2017-2019, the company did not have debt costs caused by the company's policy,
namely the implementation of the liquidity risk management policy from 2017-2019 where
SIDO mitigated liquidity risk by analyzing the availability of cash flows and funding structure
so that the resulting performance could meet the funding of the company's operating activities
in the next period. The company monitors its every liquidity need by monitoring the schedule
of payment of financial liabilities and cash outflows related to day-to-day operations, to ensure
the availability of sufficient funding, both binding and non-binding. That way from 2017-2019,
the company's capital structure does not have a combination of capital costs but is only financed
by 100% equity. In 2017 the cost of equity was 7.73%. In 2018 the cost of equity was 7.98%.
In 2019 the cost of equity was 16.66%.
The calculation results of the WACC TSPC for the 2017-2019 period have increased
relatively. In 2017 it was 5.53% an increase in 2018 by 5.95% and an increase in 2019 by
14.26%. Such fluctuations in the value of WACC are due to the composition and costs of its
capital structure. In 2017 the proportion of debt was lower than the proportion of equity at
31.65% and 68.35%. As for the cost of debt of 0.70% and the cost of equity of 7.76%. In 2018
the proportion of debt was lower than the proportion of equity, namely 30.97% and 69.03%.
As for debt costs of 1.34% and equity costs of 8.02%. In 2019, the proportion of debt was lower
than the proportion of equity, namely 30.83% and 69.17%. As for debt costs of 3.54% and
equity costs of 19.04%.
Capital Structure Based on the WACC Approach
In carrying out its activities the company is inseparable from the capital. Generally, capital
is adjusted to the company's business needs starting from the source of funding to the need for
the funding (Rita, 2019). The calculation of the proportion of the composition of the capital
structure in the pharmaceutical industry can be seen in the following Table 4:
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1280 Interdisciplinary Social Studies, 1(10), Jul 2022
Table 4. Proportion and Composition of Capital Structure of the Pharmaceutical Industry for
the Period of 2017-2019
Proportion and Composition of Capital Structure
Issuer
Account
Year
Average Issuer
2017
2018
2019
DVLA
Liability
0,00%
0,00%
0,00%
0,00%
Equity
100,00%
100,00%
100,00%
100,00%
INAF
Liability
65,59%
65,57%
63,51%
64,89%
Equity
34,41%
34,43%
36,49%
35,11%
KAEF
Liability
57,80%
64,52%
59,61%
60,64%
Equity
42,20%
35,48%
40,39%
39,36%
KLBF
Liability
16,38%
15,71%
17,56%
16,55%
Equity
83,62%
84,29%
82,44%
83,45%
MERK
Liability
0,00%
0,00%
0,00%
0,00%
Equity
100,00%
100,00%
100,00%
100,00%
PYFA
Liability
31,78%
36,42%
34,63%
34,28%
Equity
68,22%
63,58%
65,37%
65,72%
SIDO
Liability
0,00%
0,00%
0,00%
0,00%
Equity
100,00%
100,00%
100,00%
100,00%
TSPC
Liability
31,65%
30,97%
30,83%
31,15%
Equity
68,35%
69,03%
69,17%
68,85%
Source: Financial Statements, Data Processed
In table 4 above, it explains the average value of each proportion and composition of the
capital structure of healthcare issuers in the pharmaceutical sub-sector category DES listed on
the Indonesia Stock Exchange for the 2017-2019 period dominated by issuers whose capital
structure is dominated by equity including DVLA, KLBF, MERK, PYFA, SIDO, and TSPC.
Meanwhile, the capital structure of INAF and KAEF issuers is dominated by debt. To find out
the content of each cost in the company's acquisition, you can see the cost of capital in
companies in the pharmaceutical industry, it can be seen in Table 5 as follows:
Table 5. Average Value of WACC Pharmaceutical Industry for the Period of 2017-2019
Company
WACC (%)
Average
Issuer
2017
2018
2019
DVLA
7,89%
8,01%
1,90%
5,93%
INAF
3,71%
4,11%
35,10%
14,31%
KAEF
5,89%
5,05%
3,83%
4,92%
KLBF
6,96%
7,90%
5,27%
6,71%
MERK
7,73%
8,00%
1,29%
5,67%
PYFA
5,32%
5,68%
10,33%
7,11%
SIDO
7,73%
7,98%
16,66%
10,79%
TSPC
5,53%
5,95%
14,26%
8,58%
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1281 Interdisciplinary Social Studies, 1(10), Jul 2022
Industry Average
8,00%
Source: Financial Statements, data processed
The average WACC in the table above is an indicator to measure the rate of return expected
by investors or creditors towards healthcare issuers in the pharmaceutical sub-sector category
DES listed on the Indonesia Stock Exchange for the 2017-2019 period when they invest or lend
their funds to these issuers. In table 5, it can be seen that INAF, SIDO, and TSPC have an
average WACC of 14.31%, 10.79%, and 8.58% respectively above the industry WACC
average of 8.00%.
The high WACC of the three issuers signals management to evaluate its capital structure
which is quite risky. This percentage is quite profitable for investors, but on the other hand, the
amount of value is a burden of responsibility that needs to be paid by the company, even though
the funding is used for working capital and investment purposes. INAF has a capital structure
composition dominated by liabilities, while SIDO and TSPC have a capital structure
composition that is dominated by equity or own capital.
Meanwhile, other companies, namely DVLA, KAEF, KLBF, MERK, and PYFA, have an
average WACC of 5.93%, 4.92%, 6.71%, and 5.67%, and 7.11% respectively below the
industry WACC average of 8.00%. These issuers have a composition of capital structure that
is dominated by equity or own capital, including KAEF.
Of the 5 issuers that have low WACC issuers with the lowest average, WACC is KAEF,
this is because the dominance of large debt makes WACC a small company. Meanwhile,
WACC issuers DVLA, KLBF, MERK, and PYFA are below the industry average caused of
the composition of the capital structure which is dominated by the cost of equity or own capital
so that there is little risk for the company to bear the payment obligations caused by debt.
Company Value and Optimal Capital Structure
According to Brigham and Houston (2019), “The optimal capital structure is the mix of
debt, preferred stock, and common equity that maximizes the stock’s intrinsic value. As we will
see, the capital structure that maximizes the intrinsic value also minimizes the WACC”. This
means that the smaller the weighted average cost of capital, the more it will be able to maximize
profits and will maximize the value of the company.
The calculation of the company's value in the DES category of pharmaceutical industry
companies listed on the IDX for the 2017-2019 period can be seen in the appendix of each
issuer. The results of the calculation of the value of the enterprise in table 6 are as follows:
Table 6. Value of Pharmaceutical Industry Issuers for the 2017-2019 Period
Issuer
2017
2018
2019
DVLA
IDR 364,283
IDR 343,836
IDR 367,312
INAF
-IDR 21,081
-IDR 82,943
-IDR 89,299
KAEF
-IDR 3,147,950
-IDR 2,302,744
-IDR 460,804
KLBF
IDR 2,812,935
IDR 2,845,287
IDR 2,786,875
MERK
IDR 67,841
IDR 219,653
IDR 62,999
PYFA
IDR 76,899
IDR 68,165
IDR 66,918
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1282 Interdisciplinary Social Studies, 1(10), Jul 2022
SIDO
IDR 692,579
IDR 1,001,414
IDR 739,275
TSPC
IDR 777,907
IDR 1,055,046
IDR 738,852
Source: Financial Statements (Presented in Millions of Rupiah), Data Processed
DVLA recorded a positive value and relatively increased, due to the relatively increasing
growth rate of DVLA's operating profit. The decline in the company's value in 2018 was caused
by a negative individual beta value, which is contrary to positive market movements.
INAF recorded a negative value and continued to increase due to the amount of bank loan
debt and accounts payable which is increasing every year for working capital and investment
purposes such as the establishment of a Large Volume Parenteral (LVP) factory in Eastern
Indonesia as a follow-up to the signing of the Joint Venture Business cooperation. In addition,
the company received approval for the restructuring of short-term to long-term loans from PT
Bank Mandiri (Persero) Tbk and PT Bank Negara Indonesia (Persero) Tbk for the credit
facility, this condition makes the company look unhealthy and risky.
KAEF recorded a negative but declining value, this was due to the repayment of medium-
term notes in 2019. In addition, the amount of debt in the previous year was due to bank debt
for working capital loans of both parent and subsidiary entities, installments of operational
vehicles, withdrawal of investment loans used for the construction of the Banjaran plant in
Bandung, repayment, and issuance of medium-term loans for working capital, routine
investment and business development, as well as the acquisition of PT Pharos Tbk.
KBLF recorded a positive value and increased, due to an increase in the amount of
operating profit and Net Operating After Tax (NOPAT) every year and KLBF is the only
pharmaceutical issuer that gets a tax incentive of 20% from 25% because it meets the provisions
in the opportunity to get tax incentives from government policies on issuers in the capital
market. In addition, KLBF is the largest private pharmaceutical company that recorded a
positive value far above the industry average in addition to being a market leader in Indonesia,
the company has also explored the international world by exporting its products to various
foreign countries in Asia and Africa.
MERK recorded a positive value and relatively increased due to sales growth, in addition
to a drastic increase in 2018 due to the closure of operations related to the manufacturing of
MERK-owned consumer goods companies in Singapore and posted a large profit of Rp.
1,125,946,429,000.,- or 1.1 trillion.
PYFA recorded a positive value but decreased but the company's operating profit and cash-
free money bookkeeping increased every year. The decline in the value of the company occurs
because the variable in calculating the value of firms there is the cost of equity of the company
which increases every year besides that the individual beta of the company is dominated by
negative values so that the movement of the company's returns is opposite to the index in the
capital market which is positively valued.
SIDO recorded a positive value and relatively increased due to the relatively increasing
growth rate of SIDO's operating profit. The decline in the company's value in 2019 was due to
an increase in the company's cost of capital by 8.68% from the previous year.
TSPC recorded a positive value and decreased relatively due to the cost of bank debt for
working capital. In addition, there was a decrease in value in 2019 due to an increase in the
company's cost of capital by 8.32% from the previous year.
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1283 Interdisciplinary Social Studies, 1(10), Jul 2022
Table 7. Average Value and WACC of Pharmaceutical Industry Issuers for the 2017-2019
Period
Issuer
Average Company Value
Average WACC
DVLA
IDR 358,477
5,93%
INAF
-IDR 64,441
14,31%
KAEF
-IDR 1,970,499
4,92%
KLBF
IDR 2,815,032
6,71%
MERK
IDR 116,831
5,67%
PYFA
IDR 70,661
7,11%
SIDO
IDR 811,089
10,79%
TSPC
IDR 857,268
8,58%
Industry Average
IDR 374,302
8,00%
Source: Financial Statements (Presented in Millions of Rupiah), Data Processed
As it is known that the previous concept explained that the value of the company will be
maximum if the company minimizes its capital costs (WACC). Table 7 is a calculation of the
average value of the company and WACC to analyze the optimal capital structure. The concept
of optimal capital structure does not apply to SIDO and TSPC because even though SIDO and
TSPC have a high WACC, which is 10.79% and 8.58% above the industry average WACC of
8.00% of these issuers have a positive value above the average value of other pharmaceutical
industry companies that have a high WACC, namely INAF which has a negative value below
the average industrial value of the company even though the WAC is high. This is because
these issuers have a capital structure component dominated by their capital or equity, in
addition to that SIDO and TSPC record positive performance every year.
Meanwhile, DVLA, KAEF, KLBF, MERK, and PYFA have WACC of 5.93%, 4.92%,
6.71%, 5.67%, and 7.11% respectively below the industry WACC average of 8.00% each and
these issuers have a proportion of the composition of the capital structure dominated by equity
or own capital except KAEF. Meanwhile, KLBF's company value is higher than the average
industry value because the issuer is a leading player in the prescription drug division in
Indonesia in 2019 alone there was an increase in sales from this 1 division by 7.1% from the
previous year or around 5.1 T the increase contributed 22.8% to KLBF's total net sales. In
addition, the nutrition division sold in the Indonesian and foreign markets recorded a sales
value of 6.6 T rupiah with a contribution to KLBF's total net sales of 29.3%. So it is not
surprising that the assets owned are very large compared to other pharmaceutical companies.
In addition, KLBF also recorded a large after-tax profit because of reducing the company
getting tax incentives to 20% and positioned as the only pharmaceutical issuer that received
tax incentives. Meanwhile, the value of DVLA, KAEF, MERK, and PYFA companies is still
below the industry average even though wacc is low so these issuers cannot be said to be
optimal.
Thus according to the concept of optimal capital structure of PT. PT. Kalbe Farma Tbk.
(KBLF) already has an optimal capital structure because it has a low WACC below the industry
average and a high company value above the industry average. The policy of issuers who record
a positive value is in line with the pecking order theory where this theory argues to determine
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1284 Interdisciplinary Social Studies, 1(10), Jul 2022
funding starting from the lowest risk, namely from equity or own capital accounts to those with
high risk, namely debt through liability accounts.
Implications of Research Results
Based on the results of the analysis and optimal capital structure of companies with a
weighted average cost of capital (WACC) approach, in healthcare issuers in the pharmaceutical
sub-sector of the DES category listed on the IDX for the 2017-2019 period, there are still
companies that do not have an optimal capital structure even though WACC is below the
industry average compared to KLBF as experienced by DVLA, KAEF, MERK, and PYFA
from the results of the study indicated that the company still does not maximize its performance
the company from the existing funding although the composition of the company's capital
structure is dominated by its capital (Ordinary shares), except KAEF where it is dominated by
debt, KAEF continues to make improvements as evidenced by the decline in its debt capital
structure which is moving in a positive direction. While on the other hand there are companies
that have high WACC and high company value, as experienced by SIDO and TSPC. Where
the cost of capital is the rate of return expected by investors on their investments, both
companies have a fairly high expectation of a rate of return for investors or creditors who want
to provide loans in the form of debt to the company.
For companies that do not have an optimal capital structure as experienced by INAF, there is a
proportion of the composition of the capital structure that is dominated by debts or liabilities,
it is better if the company's management is more careful and careful in determining its capital
structure even for working capital and or for investment to achieve an optimal combination to
increase the value of the company and reduce company risks.
CONCLUSION
Based on the results of the study, it was found that the average proportion and composition
of the capital structure of healthcare issuers in the pharmaceutical subsector in the DES
category listed on the IDX for the 2017-2019 period were dominated by equity or own capital
including, (DVLA), (KLBF), (MERK), (PYFA), (SIDO) and (TSPC). Even DVLA and SIDO
do not have great exposure to cost-oriented loans. Meanwhile, (INAF) and (KAEF) have a
proportion of the composition of the capital structure that is dominated by debt or liabilities.
Based on the calculation of the weighted average cost of capital (WACC), it can be known
that the industry average WACC in the pharmaceutical subsector healthcare issuers in the DES
category listed on the IDX for the 2017-2019 period is 8.00%. INAF, SIDO, and TSPC have a
WACC above the average WACC of the pharmaceutical industry of 14.31%, 10.79%, and
8.58%, respectively. This indicates that these issuers have a higher expected rate of return than
other issuers in the pharmaceutical industry. This expected return can be considered by
investors if they invest in the issuer and or creditors who provide loans in the form of debt to
the company, on the other hand, the level of capital costs is a burden that must be cashed in by
the company. Meanwhile, DVLA, KAEF, KLBF, MERK, and PYFA have WACC below the
industry average of 5.93%, 4.92%, 6.71%, 5.67%, and 7.11%, respectively, which indicates a
low expected return for claim holders.
Based on the calculation of the company's value, it can be known the average company
value of the industry in the healthcare issuer of the pharmaceutical subsector in the DES
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1285 Interdisciplinary Social Studies, 1(10), Jul 2022
category listed on the IDX for the 2017-2019 period in millions of rupiah, amounting to Rp.
374,302,-. KLBF, SIDO, and TSPC have a company value of Rp. 2,815,032,-, Rp. 811,089, -
and Rp. 857,268, respectively, where the value of the issuers is above the average value of
pharmaceutical industry companies. Meanwhile, DVLA, INAF, KAEF, MERK, and PYFA
have a lower company value of Rp. 358,477,,-, (Rp. 64,441,-), (Rp. 1,970,499,-), Rp. 116,831,
- and Rp. 70,661, respectively, - compared to the average company value of the industry.
Based on the results of the study, it was found that the average optimal capital structure of
healthcare issuers in the pharmaceutical subsector of the DES category listed on the IDX for
the 2017-2019 period has an average industrial WACC of 8.00% and an average industrial
company value of Rp. 374,302,-. There is a KLBF with WACC below the industry average and
the company value is above the industry average where the value is 6.71% and Rp. 2,815,032,-
respectively. Meanwhile, DVLA, MERK, and PYFA are not optimal because the company's
value is below the industry average even though WACC is low. INAF is not optimal because
it has a WACC above the industry average value and the company value is below the industry
average. SIDO and TSPC are not optimal because the company's WACC is above the industry
average even though the company's value is above the industry average. KAEF is also not
optimal even though WACC is below the industry average but the company's value is below
the industry average and is recorded as negative.
REFERENCES
Achmad, R. (2018). Manajemen Keuangan II (No. 2; 3).
Amdalena, A. (2021). Analisis Ukuran Perusahaan Dan Pertumbuhan Penjualan Terhadap
Kebijakan Hutang Dengan Profitabilitas Sebagai Variabel Moderating Pada Perusahaan
Farmasi Yang Terdaftar Di Bursa Efek Indonesia. Kumpulan Karya Ilmiah Mahasiswa
Fakultas Sosial Sains, 1(01).
Atiqoh, Z., & Asyik, N. F. (2016). Pengaruh kinerja keuangan, size, pertumbuhan penjualan,
dan kepemilikan saham terhadap struktur modal. Jurnal Ilmu Dan Riset Akuntansi (JIRA),
5(5).
Brigham, E. F., & Houston, J. F. (2019). Fundamentals of Financial Management 15 Edition
(15th ed.). Cengage Learning.
Diarga, A. G. (2020). Analisis Persepsi Bisnis Terhadap Persepsi Konsumen Melalui Indeks
Tendensi Bisnis (ITB) dan Indeks Tendensi Konsumen (ITK) di Indonesia. Cendekia
Niaga, 4(2), 70–84.
Elvina, D., Rismala, L. I., & Sunardi, N. (2021). Analisis Penetapan Struktur Modal yang
Optimal untuk Meningkatkan Nilai Perusahaan (Studi pada Industri Pertambangan PT.
Bukit Asam Tbk Tahun 2015-2019). Jurnal SEKURITAS (Saham, Ekonomi, Keuangan
Dan Investasi), 5(1), 13–24.
Islami, R. G. (2020). (Discounted Cash Flow) Dalam Pengambilan Keputusan Investasi Pada
Perusahaan Pertambangan Tahun 2015 – 2019. Jurnal Mahasiswa USM: Pasar Modal,
1(1), 1–15.
Netriyana. (2014). Analisis Struktur Modal Yang Optimum Pada Perusahaan Telekomunikasi
Yang Terdaftar Di BEI. INSTITUT PERTANIAN BOGOR (IPB).
Capital Structure Analysis in Healthcare Issuers in the DES Category for 2017-2019
1286 Interdisciplinary Social Studies, 1(10), Jul 2022
Pantow, M. S. R., Murni, S., & Trang, I. (2015). Analisa pertumbuhan penjualan, ukuran
perusahaan, return on asset, dan struktur modal terhadap nilai perusahaan yang tercatat di
indeks lq 45. Jurnal EMBA: Jurnal Riset Ekonomi, Manajemen, Bisnis Dan Akuntansi,
3(1).
Rahma, S., Darminto, & Topowijono. (2014). Analisis Penetapan Struktur Modal Yang
Optimal Guna Meningkatkan Nilai Perusahaan (Studi Pada PT. Seemount Garden
Sejahtera, Jiwan, Kabupaten Madiun Periode 2011-2013). JAB UB: Jurnal Administrasi
Bisnis Universitas Brawijaya, 13(1), 1–10.
Rita, M. R. (2019). Potret pendanaan UMKM berdasarkan siklus hidup usaha. EBBANK, 9(2),
27–34.
Septantya, A., Dzulkirom, M., & Azizah, D. (2015). Penentuan Struktur Modal Yang Optimal
Dalam Rangka Meningkatkan Nilai Saham Perusahaan (Studi Pada PT. Perusahaan Gas
Negara (Persero) Tbk. JAB UB: Jurnal Administrasi Bisnis Universitas Brawijaya, 29(1),
10–18.
Sulistio, A., & Saifi, M. (2017). Analisis Penentuan Struktur Modal Yang Optimal Untuk
Meningkatkan Nilai Perusahaan (Studi Pada PT. Astra Graphia Tbk. Periode 2013-2015).
JAB UB: Jurnal Administrasi Bisnis Universitas Brawijaya, 48(1), 37–45.
Suranto, V. A. H. M., & Walandouw, S. K. (2017). Analisis pengaruh struktur modal dan
kinerja keuangan terhadap nilai perusahaan pada perusahaan perbankan di Bursa Efek
Indonesia. Jurnal EMBA: Jurnal Riset Ekonomi, Manajemen, Bisnis Dan Akuntansi, 5(2).
Yuliana, S., & Wijayanti, R. (2017). Analisis Struktur Modal Pada Perusahaan Industri Semen
Yang Terdaftar Di Bursa Efek Indonesia Periode 2013-2015. JIMFEB UB: Jurnal Ilmiah
Mahasiswa Fakultas Ekonomi Dan Bisnis Universitas Brawijaya, 5(2), 2–18.
https://doi.org/10.24256/alw.v3i2.492